Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 6083-6094

  Smith, Michael A ^a   Lim, Alice ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Direct acting antiviral; Interferon free; Ribavirin free

Indexed keywords

ALFUZOSIN; AMLODIPINE; CARBAMAZEPINE; CYCLOSPORIN; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EFAVIRENZ; ERGOTAMINE; GEMFIBROZIL; KETOCONAZOLE; MEVINOLIN; OLMESARTAN; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PLACEBO; PRAVASTATIN; RIBAVIRIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; SALMETEROL; SIMVASTATIN; TACROLIMUS; TELAPREVIR; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; CARRIER PROTEIN; MACROCYCLIC COMPOUND; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; SULFONAMIDE; URACIL; VIRAL PROTEIN;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; BODY MASS; CHILD PUGH SCORE; CHRONIC HEPATITIS C; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; NAUSEA; PRURITUS; RASH; RELAPSE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION; VIRUS REPLICATION; VOLUME OF DISTRIBUTION; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; CARRIER PROTEINS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MOLECULAR TARGETED THERAPY; PROTEASE INHIBITORS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; URACIL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84947461351     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S80226     Document Type: Review

References (38)

1. World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. Geneva: World Health Organization; 2014.
2. Smith BD, Morgan RL, Beckett GA, et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
3. Hepatitis C Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C [webpage on the Internet]. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). Available from: http://www.hcvguidelines.org/. Accessed September 10, 2015.
4. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) copackaged for oral use [prescribing information]. North Chicago: AbbVie Inc; 2015.
5. Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59(2):988-997.
6. Gentile I, Borgia F, Buonomo AR, Zappulo E, Castaldo G, Borgia G. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2014;21(28):3261-3270.
7. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15(5):1313-1322.
8. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85(14):7312-7320.
9. DeGoey DA, Randolph JT, Liu D, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014;57(5):2047-2057.
10. Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther. 2013;7:1223-1233.
11. Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12(9):1033-1043.
12. Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59(2):979-987.
13. Kati W, Koev G, Irvin M, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59(3):1505-1511.
14. Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials. 2014;9(2):115-123.
15. Khatri A, Menon R, Marbury TC, et al. Pharmacokinetics and safety of coadministered paritaprevir plus ritonavir (paritaprevir/r), ombitasvir, and dasabuvir in hepatic impairment. J Hepatol. Epub 2015 Jun 10.
16. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-1603.
17. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.
18. Ferenci P, Bernstein D, Lalezari J, et al; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
19. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147(2):359-365.e1.
20. Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. Epub 2015 Jul 3.
21. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-1982.
22. Feld JJ, Moreno C, Trinh R, et al. Turquoise-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis. [Abstract P226.] 15th Annual International Symposium on Viral Hepatitis and Liver Disease. June 26-28, 2015; Berlin, Germany.
23. Chayama K, Notsumata K, Kurosaki M, et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015;61(5):1523-1532.
24. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223-1231.
25. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375-2382.
26. Toussaint-Miller KA, Andres J. Treatment considerations for unique patient populations with HCV genotype 1 infection. Ann Pharmacother. 2015;49(9):1015-1030.
27. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-569.
28. Pockros PJ, Reddy KR, Mantry PS, et al. L01: safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the Ruby-I study. J Hepatol. 2015;62:S257-S261.
29. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29.
30. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63(2):364-369.
31. Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015;49(6):674-687.
32. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11(3):333-341.
33. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol. 2004;85(Pt 11):3173-3188.
34. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010;2(30):30ra32.
35. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55(1):192-206.
36. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48(6):1769-1778.
37. Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat. 2014;21(4):229-240.
38. Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. Epub 2015 Jun 10.